Curis skyrockets 448% after encouraging phase 1 data for leukemia treatment
- Small-cap biotechnology firm Curis surged as much as 448% on Tuesday after the company released encouraging phase I data for its leukemia treatment, CA-4948.
- The company said it observed a Marrow complete response in two patients, as well as a reduction of marrow blasts observed in all evaluable patients in the study.
- The company expects to report additional phase I data of the study in the second half of 2021.
- Visit Business Insider's homepage for more stories.
Curis, Inc. staged an eye-popping rally on Tuesday after it released positive preliminary data related to its phase one trial of CA-4948, a small molecule inhibitor that is being tested in patients with acute myeloid leukemia.
Curis shares jumped as much as 448% in Tuesday trades to $7.90. The stock closed at $1.44 on Monday.
The positive preliminary data from the phase one trial included marrow blast reductions observed in all evaluable patients, as well as two patients experiencing a marrow complete response, according to the company.
Dr. Guillermo Garcia-Manero of The University of Texas MD Anderson Cancer Center said, "These preliminary data suggest, for the first time in a clinical setting, that successfully targeting the long isoform of IRAK4...could be the first major breakthrough in over a decade for patients with these diseases."
Curis will continue to advance the study of CA-4948 and expects to report additional phase one data in the second half of 2021.
